RT Journal Article
SR Electronic
T1 Evaluating the Effect of Prebiotics on the Gut Microbiome Profile and β-cell Function in Youth with Newly-Diagnosed Type 1 Diabetes: Protocol of a Randomized Controlled Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.05.20207142
DO 10.1101/2020.10.05.20207142
A1 Heba M. Ismail
A1 Maria Spall
A1 Carmella Evans-Molina
A1 Linda A. DiMeglio
YR 2021
UL http://medrxiv.org/content/early/2021/04/16/2020.10.05.20207142.abstract
AB Introduction Data show that disturbances in the gut microbiota play a role in glucose homeostasis, type 1 diabetes (T1D) risk and progression. The prebiotic high amylose maize starch (HAMS) alters the gut microbiome profile and metabolites favorably with an increase in bacteria producing short chain fatty acids (SCFAs) that have significant anti-inflammatory effects. HAMS also improves glycemia, insulin sensitivity and secretion in healthy non-diabetic adults. Additionally, a recent study testing an acetylated and butyrylated form of HAMS (HAMS-AB) that further increases SCFA production prevented T1D in a rodent model without adverse safety effects. The overall objective of this human study will be to assess how daily HAMS-AB consumption impacts the gut microbiome profile, SCFA production, β-cell heath, function and glycemia as well as immune responses in newly-diagnosed T1D youth.Methods and Analysis We hypothesize that HAMS-AB intake will improve the gut microbiome profile, increase SCFA production, improve β-cell health, function and glycemia as well as modulate the immune system. We describe here a pilot, randomized crossover trial of HAMS-AB in 12 newly-diagnosed T1D youth with residual β-cell function. In Aim 1, we will determine the effect of HAMS-AB on the gut microbiome profile and SCFA production; in Aim 2, we will determine the effect of HAMS-AB on β-cell health, function and glycemia; and in Aim 3, we will determine the peripheral blood effect of HAMS-AB on frequency, phenotype and function of specific T cell markers. We anticipate beneficial effects from a simple, inexpensive, and safe dietary approach.Ethics and Dissemination The Institutional Review Board at Indiana University approved the study protocol. The findings of this trial will be submitted to a peer-reviewed pediatric journal. Abstracts will be submitted to relevant national and international conferences.Trial registration number NCT04114357; Pre-results.Strengths and limitations of this studyThe study design (randomized controlled trial, RCT) is the most robust methodology to assess the effectiveness of therapeutic interventions.The findings of this RCT, whether positive or negative, will contribute to the formulation of further recommendations on the use of high amylose maize starch that has been acetylated and butyrylated for improving beta-cell function in children with newly diagnosed type 1 diabetes (T1D).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04114357Funding StatementWe acknowledge the support from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award, Grant Numbers, KL2TR002530 (A Carroll, PI), and UL1TR002529 (A. Shekhar, PI). We also acknowledge support from the IU Health Values grant and the Indiana CTSI Project Development Team.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Indiana University IRB, protocol number 1907172784All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data will be generated during the study. Requests for sharing of available data and samples will be granted on a case by case basis.